Skip to content

Opko Health OPK Free cash flow yield

Free cash flow yield at other companies

Quest Diagnostics logo
Quest DiagnosticsDGX
6.2%+0.5pp
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
-24.3%
HRO
HarrowHROW
1.2%+1.0pp
Precigen logo
PrecigenPGEN
-8.5%-2.9pp
Immunome logo
ImmunomeIMNM
-8.3%-3.4pp
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-24.4%-252pp

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.13B+10.0%
P/S1.9×+0.5×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0.0×
Current ratio3.6×+1.1×

Where this comes from

Calculated from Opko Health’s reported figures.

Based on trailing twelve months.

The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's free cash flow yield?
Opko Health (OPK) reported free cash flow yield of -20.1% in Q1 2026.
How has Opko Health's free cash flow yield changed year-over-year?
Opko Health's free cash flow yield decreased by 8.8% year-over-year, from -18.5% to -20.1%.
What is the long-term trend for Opko Health's free cash flow yield?
Over 3 years (2020 to 2025), Opko Health's free cash flow yield has grown at a 341.7% compound annual growth rate (CAGR), from 0.2% to -19.7%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.